{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2FSaline+solution&page=2",
    "query": {
      "intervention": "Placebo/Saline solution",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo%2FSaline+solution&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-17T13:59:37.540Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01821118",
      "title": "Study Evaluating the Safety,Tolerability and Efficacy of PF-04360365 in Adults With Probable Cerebral Amyloid Angiopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cerebral Amyloid Angiopathy"
      ],
      "interventions": [
        {
          "name": "Ponezumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "55 Years to 90 Years"
      },
      "enrollment_count": 36,
      "start_date": "2013-06",
      "completion_date": "2015-09",
      "has_results": true,
      "last_update_posted_date": "2017-05-10",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 7,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Charlestown, Massachusetts + 2 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlestown",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01821118"
    },
    {
      "nct_id": "NCT04589403",
      "title": "1a/1b Study of OPT101 First in Human Study Assessing Safety and Tolerability of 15-mer Peptide.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "OPT101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Op-T LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 14,
      "start_date": "2021-02-18",
      "completion_date": "2021-09-27",
      "has_results": false,
      "last_update_posted_date": "2025-09-15",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 1,
      "location_summary": "Centennial, Colorado",
      "locations": [
        {
          "city": "Centennial",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04589403"
    },
    {
      "nct_id": "NCT04518410",
      "title": "ACTIV-2: A Study for Outpatients With COVID-19",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Coronavirus",
        "Covid19"
      ],
      "interventions": [
        {
          "name": "bamlanivimab 7000mg",
          "type": "BIOLOGICAL"
        },
        {
          "name": "BRII-196+BRII-198",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IV)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "AZD7442 (IM)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SNG001",
          "type": "DRUG"
        },
        {
          "name": "Camostat",
          "type": "DRUG"
        },
        {
          "name": "BMS-986414 + BMS-986413",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (3,840 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "SAB-185 (10,240 Units/kg)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "CASIRIVIMAB + IMDEVIMAB",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 7000mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Bamlanivimab 700mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BRII-196+BRII-198",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SNG001",
          "type": "DRUG"
        },
        {
          "name": "Placebo for Camostat",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for BMS-986414 + BMS-986413",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IV)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for AZD7442 (IM)",
          "type": "DRUG"
        },
        {
          "name": "Placebo for SAB-185 (high dose)",
          "type": "DRUG"
        },
        {
          "name": "bamlanivimab 700mg",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4044,
      "start_date": "2020-08-19",
      "completion_date": "2023-06-20",
      "has_results": true,
      "last_update_posted_date": "2024-08-02",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 207,
      "location_summary": "Anniston, Alabama • Athens, Alabama • Birmingham, Alabama + 143 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Athens",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Cullman",
          "state": "Alabama"
        },
        {
          "city": "Jasper",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04518410"
    },
    {
      "nct_id": "NCT07482423",
      "title": "XVIE to Treat Androgenetic Alopecia (AGA)",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Androgenetic Alopecia"
      ],
      "interventions": [
        {
          "name": "Decellularized allogeneic human amniotic fluid",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Sodium chloride 0.9% injectable solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Restore Biologics Holdings, Inc. dba Xtressé",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 30,
      "start_date": "2026-12-01",
      "completion_date": "2028-05-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-12",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 2,
      "location_summary": "Orlando, Florida • Marriottsville, Maryland",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Marriottsville",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07482423"
    },
    {
      "nct_id": "NCT07133880",
      "title": "Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "COPD (Chronic Obstructive Pulmonary Disease)"
      ],
      "interventions": [
        {
          "name": "umeclidinium 62.5 µg and vilanterol 25 µg",
          "type": "DRUG"
        },
        {
          "name": "Revefenacin 175 µg, Formoterol 20 µg",
          "type": "DRUG"
        },
        {
          "name": "Placebo ( Revefenacin and Formoterol )",
          "type": "DRUG"
        },
        {
          "name": "Placebo DPI",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Tennessee Graduate School of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2023-12-05",
      "completion_date": "2026-12-01",
      "has_results": false,
      "last_update_posted_date": "2026-08-17",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 1,
      "location_summary": "Knoxville, Tennessee",
      "locations": [
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07133880"
    },
    {
      "nct_id": "NCT05953480",
      "title": "A Phase 2b, Randomized, Double-blind Study of Redasemtide (S-005151) in Adult Participants With Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Redasemtide",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 680,
      "start_date": "2023-07-14",
      "completion_date": "2026-06-15",
      "has_results": false,
      "last_update_posted_date": "2026-07-30",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 17,
      "location_summary": "Tucson, Arizona • Sarasota, Florida • Augusta, Georgia + 14 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Rockford",
          "state": "Illinois"
        },
        {
          "city": "Munster",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05953480"
    },
    {
      "nct_id": "NCT01664559",
      "title": "Pain Control for Intrauterine Device Placement: A Trial of Ketorolac Prior to Intrauterine Device Placement",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pain Control With IUD Insertion"
      ],
      "interventions": [
        {
          "name": "Ketorolac",
          "type": "DRUG"
        },
        {
          "name": "Normal Saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lynn Ngo",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 67,
      "start_date": "2012-07",
      "completion_date": "2014-03",
      "has_results": true,
      "last_update_posted_date": "2015-12-23",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01664559"
    },
    {
      "nct_id": "NCT05717062",
      "title": "Broad-spectrum Rapid Antidote: Varespladib IV to Oral Trial for Snakebite (BRAVIO)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Snakebite",
        "Envenoming, Snake"
      ],
      "interventions": [
        {
          "name": "Varespladib intravenous form",
          "type": "DRUG"
        },
        {
          "name": "varespladib-methyl- oral form",
          "type": "DRUG"
        },
        {
          "name": "Placebo intravenous form",
          "type": "DRUG"
        },
        {
          "name": "Placebo - oral form",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ophirex, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2023-05-30",
      "completion_date": "2025-02-24",
      "has_results": false,
      "last_update_posted_date": "2025-06-27",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Tucson, Arizona • Palm Springs, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "Rosamond",
          "state": "California"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05717062"
    },
    {
      "nct_id": "NCT02492269",
      "title": "Stress Response and Neurodevelopmental Outcome After Cardiac Surgery Utilizing CPB in Children: A Prospective, Double Blinded and Randomized Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Congenital Heart Disease"
      ],
      "interventions": [
        {
          "name": "Dexmedetomidine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aymen N Naguib",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Month",
        "maximum_age": "12 Months",
        "sex": "ALL",
        "summary": "1 Month to 12 Months"
      },
      "enrollment_count": 30,
      "start_date": "2014-05",
      "completion_date": "2024-12",
      "has_results": true,
      "last_update_posted_date": "2025-08-07",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02492269"
    },
    {
      "nct_id": "NCT01147341",
      "title": "Can TNF-Alpha Incomplete Secondary Responders Attain a Safe and Efficacious Response Switching to Cimzia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "Cimzia",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael Schiff, MD",
      "sponsor_class": "INDIV",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 37,
      "start_date": "2010-07",
      "completion_date": "2012-01",
      "has_results": true,
      "last_update_posted_date": "2014-06-09",
      "last_synced_at": "2026-09-17T13:59:37.540Z",
      "location_count": 12,
      "location_summary": "Huntsville, Alabama • Peoria, Arizona • Phoenix, Arizona + 9 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Peoria",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sarasota",
          "state": "Florida"
        },
        {
          "city": "Lincoln",
          "state": "Nebraska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01147341"
    }
  ]
}